ArticlePharmacology research & perspectives2026
Network Pharmacology Combined With Clinical Retrospective Analysis to Investigate the Potential Mechanisms and Clinical Significance of Folate in Treating Spinal Cord Injury.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Folate is an indispensable nutrient involved in key biological processes, including enzymatic reactions, DNA replication, metabolic regulation, and methylation. Studies indicate that folate promotes neuronal regeneration and repair in patients with spinal cord injury (SCI); however, its precise mechanisms remain unclear. We employed network pharmacology to identify potential targets of folate for SCI treatment; we conducted a clinical retrospective study, selecting 50 SCI patients and 50 non-SCI control subjects from Tianjin Hospital between 2022 and 2025 to validate predictions by assessing serum folate levels. Network pharmacology identified 1402 folate-related targets and 548 SCI-related targets. Key targets included TNF-α, CASP3, EGF, IL1β, and AKT1. Molecular docking revealed the highest binding affinity between folate and CASP3/TNF-α (-8.5 kcal/mol). Clinical validation demonstrated statistically significant lower folate levels in SCI patients compared to normal levels in non-SCI controls. A strong inverse correlation was observed between folate levels and injury level (r = -0.58, p < 0.001). Folate exerts neuroprotective effects by synergistically regulating neuronal apoptosis, inflammatory responses, and oxidative stress pathways. Clinical data reveal prevalent folate deficiency in SCI patients, and this nutritional deficit may exacerbate secondary injury cascades. We recommend incorporating folate supplementation into comprehensive SCI management protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.